The N-acetylgalactosamine-transferase11 (GALNT11) activation in leukemia and the role of cyclophosphamide and cytarabine in expression of this enzyme

We investigated the activation of N-acetylgalactosamine-transferase11 (GALNT11) and the role of cyclophosphamide and cytarabine in expression of this enzyme in AML and CML patients. GALNT11 activity and expression levels were evaluated in human chronic myelogenous leukemia cells (K562) and human acute monocytic leukemia cells (THP1) after incubation with different concentrations of cyclophosphamide (Cyclo) and cytarabine (Cyta). Anti-proliferative effects of Cyclo and Cyta were examined by MTT assay. Real time-PCR and ELISA assays were applied to investigate the expression and activity of GALNT11, respectively. The IC50 values for Cyclo were 34.73±0.12 μM for K562 and 36.16±0.23 µM for THP1 cells. These valuses for Cyta were also 0.38±0.15 μM for K562 and 0.52±0.18 µM for THP1 cells. The activation and expression of GALNT11 increased in acute and chronic leukemia as glycosylation disorders. Also cyclophosphamide and specially cytarabine cause significant increase in activation and expression of GALNT11 which inhibits glycosylation and tumorogenesis dependent signaling pathway.